000			03226nam a22005295i 4500
001			978-3-540-73259-4
003			DE-He213
005			20161121230808.0
007			cr nn 008mamaa
008			100301s2008 gw | s |||| 0|eng d
020			_a9783540732594 _9978-3-540-73259-4
024	7		_a10.1007/978-3-540-73259-4 _2doi
050		4	_aRM1-950
072		7	_aMMG _2bicssc
072		7	_aMED071000 _2bisacsh
082	0	4	_a615 _223
245	1	0	_aTherapeutic Antibodies _h[electronic resource] / _cedited by Yuti Chernajovsky, Ahuva Nissim.
246	3		_aWith contributions by numerous experts
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2008.
300			_aXI, 380 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aHandbook of Experimental Pharmacology, _x0171-2004 ; _v181
505	0		_aHistorical Development of Monoclonal Antibody Therapeutics -- Preclinical Safety Evaluation of Monoclonal Antibodies -- Molecular Developments in Antibody Production -- Engineering Antibodies for Stability and Efficient Folding -- Human Monoclonal Antibodies from Transgenic Mice -- Antibodies to Cytokines -- Anti-TNF Antibodies: Lessons from the Past, Roadmap for the Future -- Therapeutic Anti-VEGF Antibodies -- Humanized Antihuman IL-6 Receptor Antibody, Tocilizumab -- Antibodies to Cell Markers -- Anti-CD20Monoclonal Antibody in Rheumatoid Arthritis and Systemic Lupus Erythematosus -- Herceptin -- The Use of CD3-Specific Antibodies in Autoimmune Diabetes: A Step Toward the Induction of Immune Tolerance in the Clinic -- Monoclonal Antibody Therapy for Prostate Cancer -- Anti-IgE and Other Antibody Targets in Asthma -- Development of Antibody-Based Cellular and Molecular Therapies -- Cytokine, Chemokine, and Co-Stimulatory Fusion Proteins for the Immunotherapy of Solid Tumors -- The T-Body Approach: Redirecting T Cells with Antibody Specificity -- Intracellular Antibodies (Intrabodies) and Their Therapeutic Potential.
520			_aAntibody therapeutics are the treatment of choice for several autoimmune and oncological conditions and are becoming the molecules of choice for further combination therapies and cell engineering. Current developments and clinical successes are summarised by experts in the drug development field. A must read for immunologists, clinical scientists and novel drug developers.
650		0	_aMedicine.
650		0	_aCancer research.
650		0	_aHuman genetics.
650		0	_aImmunology.
650		0	_aPharmacology.
650	1	4	_aBiomedicine.
650	2	4	_aPharmacology/Toxicology.
650	2	4	_aImmunology.
650	2	4	_aHuman Genetics.
650	2	4	_aCancer Research.
700	1		_aChernajovsky, Yuti. _eeditor.
700	1		_aNissim, Ahuva. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783540732587
830		0	_aHandbook of Experimental Pharmacology, _x0171-2004 ; _v181
856	4	0	_uhttp://dx.doi.org/10.1007/978-3-540-73259-4
912			_aZDB-2-SBL
950			_aBiomedical and Life Sciences (Springer-11642)
999			_c504081 _d504081